ROCKVILLE, MD--(Marketwire -06/05/12)- MarketResearch.com has announced the addition of the new report "Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016," to their collection of Diseases & Conditions market reports. For more information, visit http://www.marketresearch.com/Renub-Research-v3619/Hepatitis-HCV-Forecast-Drugs-Pipeline-6773753/
Hepatitis C virus drug market is experiencing a dramatic near-term growth, by crossing US$ 6 Billion in 2011 and is expected to be more than double of its current figure by 2015. This robust growth will be driven primarily by the launch of novel premium-priced agents that will increase the size of the drug-treated population, mainly as a result of the re-treatment of prior non-responder patients.
Pegasys, Copegus and Pegintron were the only obtainable drugs in Hepatitis C drug market till May 2011. Pegasys always had more revenue generation in any year compared to Pegintron and is also expected to have higher revenue in future till 2016. However by the end of May 2011, the dynamics of the market has changed after the launch of Incivek and Victrelis. Incivek sale has grown quickly and it garnered around US$ 400 Million by end of 3rd quarter 2011. It is expected that Incivek sales will be slightly less than US$ 4 Billion by 2015. On the other hand Victrelis, which was approved a week before Incivek, is moving along a slower adoption curve. Victrelis has lost its grip into the market and reaped only US$ 31 Million sales by the end of 3rd quarter 2011.
In respect of these there are many other pipeline drugs, which are currently in clinical trial Phase II or Phase III and expected to be launched by 2014. Pipeline drugs like Setrobuvir (ANA 598), RG-7128, TMC - 435 and Danoprevir are going to be the next game changers in the Hepatitis C drug market. Renub Research report entitled "Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016" is an essential source of information and analysis on the global HCV market. The report identifies the key trends shaping and driving the global HCV market. The report also provides insight into the prevalent competitive landscape, launched HCV drugs present and future performance, yet to be launched HCV drugs forecast. Most importantly, the report provides valuable insight into the pipeline products within the global Hepatitis C sector.
For more information, visit http://www.marketresearch.com/Renub-Research-v3619/Hepatitis-HCV-Forecast-Drugs-Pipeline-6773753/
MarketResearch.com is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, MarketResearch.com offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. Moreover, MarketResearch.com's Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance. For more information, call Veronica Franco at 240-747-3016 or visit http://www.marketresearch.com.